The duration a patient can successfully live and remain on olaparib (a targeted PARP inhibitor medication used for various cancers like ovarian, breast, and prostate cancer) varies dramatically based on individual cancer stages, treatment responses, and side effect tolerances. Clinical trial data and real-world oncology outcomes show that many patients tolerate maintenance therapy effectively for months or even several years, provided the disease remains controlled and toxicities are manageable.